Quote this publication Share Print


Opinions on drugs - Posted on Feb 06 2013

Reason for request

Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.


Actual benefit


The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient.

Contact Us

Évaluation des médicaments

See also